Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients

American Journal of Medicine

Volumn 104, Issue 1, 1998, Pages 33-39

  Graybill, John R ^a   Vazquez, Jose ^b   Darouiche, Rabih O ^c   Morhart, Robert ^d   Greenspan, Deborah ^e   Tuazon, Carmelita ^f   Wheat, L Joseph ^g   Carey, John ^h   Leviton, Ira ⁱ   Hewitt, Ross G ^j   MacGregor, Rob Roy ^k   Valenti, William ^l   Restrepo, Marcos ^a   Moskovitz, Bruce L ^m  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^g Building 98A 3C   (United States)

^h Div of Infectious Diseases   (United States)

ⁱ MONTEFIORE MEDICAL CENTER   (United States)

^j ERIE COUNTY MEDICAL CENTER   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l Community Health Network ^*  (United States)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; OROPHARYNX; PRIORITY JOURNAL; RASH; SINGLE BLIND PROCEDURE; THRUSH; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PHARYNGEAL DISEASES; SEVERITY OF ILLNESS INDEX; SOLUTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031934137     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00307-0     Document Type: Article

References (28)

1. Van Meter F, Gallo JW, Garcia-Rojas G, et al. A study of oral candidiasis in HIV-positive patients. J Dent Hyg. 68:1994;30-34.
2. Anassi EO, Egbunike IG, Akpaffiong MJ, et al. Developing and implementing guidelines to promote appropriate use of fluconazole therapy in an AIDS clinic. Hosp Pharm. 29:1994;576-578, 581\N582, 585\N586.
3. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients with human immunodeficiency virus. Antimicrob Agents Chemother. 34:1990;2267-2268.
4. Owens NJ, Nightingale CH, Schweizer RT, et al. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med. 144:1984;290-293.
5. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches . J Acq Immune Def Synd. 6:1993;1311-1316.
6. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 12:(suppl 3):1990;S334-S337.
7. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Arch Intern Med. 151:1991;2458-2464.
8. De Wit S, Goossens H, Weerts D, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989;746-748.
9. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NEJM. 332:1995;700-705.
10. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann Pharmacother. 26:1992;502-509.
11. Hay RJ, Dupont B, Graybill JR. First international symposium on itraconazole a summary . Rev Infect Dis. 9:(suppl 1):1987;S1-S3.
12. Blatchford NR. Treatment of oral candidiases with itraconazole a review . J Am Acad Dermatol. 23:1990;565-567.
13. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis. 19:1994;687-692.
14. Smith DE, Midgley J, Allan M, et al. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidiases in patients infected with HIV. AIDS. 5:1991;1367-1371.
15. Shelton MJ, Adams JM, Hewitt RG, et al. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy. 17:1997;438-444.
16. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 36:1992;477-480.
17. Data on file. Janssen Pharmaceutica, Beerse, Belgium.
18. Desmet P, Kayembe K, Stoffels P, et al. Treatment of oral candidiases in AIDS patients with itraconazole oral solution. Third Symposium, Topics in Mycology: Mycoses in AIDS Patients. Paris, France; November 20-23, 1989.
19. Murray PA, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in HIV-positive/AIDS patients. Clin Ther. 19:1997;471-480.
20. Division of AIDS table for grading severity of adult adverse experiences. Rockville, Md: National Institute of Allergy and Infectious Diseases; 1996.
21. Prentice AG, Warnock DW, Johnson SAN, et al. Multiple pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 34:1994;247-252.
22. Goff DA, Koletar SL, Buesching WJ, et al. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis. 20:1995;77-83.
23. Barchiesi F, Colombo AL, McGough DA, et al. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Chemother. 38:1994;1530-1533.
24. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 19:1994;684-686.
25. Fessel WJ, Merrill KW, Ward DJ, et al. An open-label evaluation of itraconazole oral solution in the treatment of HIV-positive or AIDS patients with fluconazole-refractory oropharyngeal candidiasis. 4th Nat Conf Human Retrovir. In press.
26. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS documentation by in vitro susceptibility testing and DNA subtype analysis . Clin Infect Dis. 18:1994;240-242.
27. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 39:1995;1-8.
28. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients colonization, infection, treatment, and emergence of fluconazole resistance . Am J Med. 97:1994;339-346.